Laurus Labs projects strong FY26 growth on CDMO momentum and generics expansion

The generics segment is also expected to post growth, supported by Contract Manufacturing Organisation (CMO) opportunities and a stable antiretroviral (ARV) business. Shares of Laurus Labs Ltd ended at ₹943.00, up by ₹19.10, or 2.07%, on the BSE.

Source link